NewLimit

NewLimit

NewLimit is a longevity biotech startup focused on reversing cellular aging through epigenetic reprogramming. The company aims to develop drugs that reset gene expression in aged cells, with plans to start human clinical trials in 2027 targeting alcohol-related liver disease. This funding round has significantly increased its valuation, reflecting strong investor confidence in its innovative approach.

Total raised
$435M
tracked to date
Latest round
Series C
Jun 3, 2026
Known investors
6
led by Founders Fund
Press coverage
3
outlets tracked

Is this your company?

Claim this profile to get matched with investors who fund Health startups in United States.

Claim this profile →

🏆 Featured in Datapile’s Q2 2026 USA Funding Report

Read the Q2 2026 USA report →
Add this badge to your site
<a href="https://datapile.co/reports/q2-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q2 2026 USA Funding Report</a>

Funding history

  1. 1
    $435MSeries CJun 3, 2026

    Led by Founders Fund

    Announcement ↗

Founder

Brian Armstrong
Brian Armstrong
CEO & Co-founder

Investors in NewLimit

Backers from this company's tracked funding rounds.

  • FFounders FundLead investorVC firm
  • VValor Equity PartnersVC firm
  • EEli Lilly VenturesVC firm
  • HHuman CapitalVC firm
  • TThrive CapitalVC firm
  • KKleiner PerkinsVC firm

NewLimit in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile